{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:11:25Z","timestamp":1780758685830,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2023YFC2706100"],"award-info":[{"award-number":["2023YFC2706100"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173897"],"award-info":[{"award-number":["82173897"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Taishan Scholar Program of Shandong Province","award":["tstp20230660"],"award-info":[{"award-number":["tstp20230660"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40272-024-00664-4","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T15:49:52Z","timestamp":1732722592000},"page":"91-102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Population Pharmacokinetics and Dose Optimization of Piperacillin in Infants and Children with Pneumonia"],"prefix":"10.1007","volume":"27","author":[{"given":"Totsapol","family":"Jirasomprasert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Yuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian-Ping","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Kun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Xiang","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"van den Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-E","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Hao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1830-338X","authenticated-orcid":false,"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"issue":"12","key":"664_CR1","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1128\/aac.38.12.2817","volume":"38","author":"MD Reed","year":"1994","unstructured":"Reed MD, Goldfarb J, Yamashita TS, Lemon E, Blumer JL. Single dose pharmacokinetics of piperacillin and tazobactam in infants and children. Antimicrob Agents Chemother. 1994;38(12):2817\u201326. https:\/\/doi.org\/10.1128\/aac.38.12.2817.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"664_CR2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2165\/00003495-198428050-00002","volume":"28","author":"B Holmes","year":"1984","unstructured":"Holmes B, Richards DM, Brogden RN, Heel RC. Piperacillin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1984;28(5):375\u2013425. https:\/\/doi.org\/10.2165\/00003495-198428050-00002.","journal-title":"Drugs"},{"issue":"1","key":"664_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1086\/514622","volume":"27","author":"JD Turnidge","year":"1998","unstructured":"Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis. 1998;27(1):10\u201322. https:\/\/doi.org\/10.1086\/514622.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"664_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/516284","volume":"26","author":"WA Craig","year":"1998","unstructured":"Craig WA. Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1\u201310. https:\/\/doi.org\/10.1086\/516284.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"664_CR5","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1592\/phco.26.9.1320","volume":"26","author":"TP Lodise","year":"2006","unstructured":"Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2006;26(9):1320\u201332. https:\/\/doi.org\/10.1592\/phco.26.9.1320.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"664_CR6","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/jac\/dkm536","volume":"61","author":"CR Frei","year":"2008","unstructured":"Frei CR, Wiederhold NP, Burgess DS. Antimicrobial breakpoints for gram- negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. J Antimicrob Chemother. 2008;61(3):621\u20138. https:\/\/doi.org\/10.1093\/jac\/dkm536.","journal-title":"J Antimicrob Chemother"},{"key":"664_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/phar.2505","volume":"41","author":"AJ Fratoni","year":"2021","unstructured":"Fratoni AJ, Nicolau DP, Kuti JL. A guide to therapeutic drug monitoring of \u03b2-lactam antibiotics. Pharmacotherapy. 2021;41:220\u201333. https:\/\/doi.org\/10.1002\/phar.2505.","journal-title":"Pharmacotherapy"},{"key":"664_CR8","unstructured":"Pfizer. Piperacillin sodium and tazobactam sodium (Zosyn) product information. 2017. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/ label\/2017\/050684s88s89s90_050750s37s38s39lbl.pdf. Accessed May 2017."},{"issue":"8","key":"664_CR9","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1517\/17425255.2010.506187","volume":"6","author":"Y Hayashi","year":"2010","unstructured":"Hayashi Y, Roberts JA, Paterson DL, Lipman J. Pharmacokinetic evaluation of piperacillin-tazobactam. Expert Opin Drug Metab Toxicol. 2010;6(8):1017\u201331. https:\/\/doi.org\/10.1517\/17425255.2010.506187.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"664_CR10","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1086\/324524","volume":"34","author":"RC Moellering","year":"2002","unstructured":"Moellering RC. The continuing challenge of lower respiratory tract infections. Clin Infect Dis. 2002;34:S1-3. https:\/\/doi.org\/10.1086\/324524.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"664_CR11","first-page":"138","volume":"39","author":"J Leowski","year":"1986","unstructured":"Leowski J. Mortality from acute respiratory infections in children under 5 years of age: global estimates. World Health Stat Q. 1986;39(2):138\u201344.","journal-title":"World Health Stat Q"},{"issue":"1","key":"664_CR12","first-page":"81","volume":"105","author":"ZF Jiang","year":"1992","unstructured":"Jiang ZF, Wang JF, Zhaori G, Gu Q, Wang XL, Liu SY. Pneumonia-one of the major health problems of infants and children in China. Chin Med J (Engl). 1992;105(1):81\u20136.","journal-title":"Chin Med J (Engl)"},{"key":"664_CR13","unstructured":"US Food and Drug Administration. Zosyn\u00ae (piperacillin and tazobactam injection) in Galaxy\u00ae containers (PL 2040 Plastic). 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/050684s096,050750s043lbl.pdf. Accessed May 2020."},{"key":"664_CR14","doi-asserted-by":"publisher","first-page":"470","DOI":"10.18433\/jpps30927","volume":"23","author":"A Marsot","year":"2020","unstructured":"Marsot A. (2020) Review of population pharmacokinetic models of first choice beta-lactam antibiotics in severely afflicted pediatric patients: discrepancy in dosage regimens. J Pharm Pharm Sci. 2020;23:470\u201385. https:\/\/doi.org\/10.18433\/jpps30927.","journal-title":"J Pharm Pharm Sci"},{"issue":"2","key":"664_CR15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40262-018-0682-1","volume":"58","author":"A Beranger","year":"2019","unstructured":"Beranger A, Benaboud S, Urien S, Moulin F, Bille E, Lesage F, et al. Piperacillin population harmacokinetics and dosing regimen optimization in critically ill children with normal and augmented renal clearance. Clin Pharmacokinet. 2019;58(2):223\u201333. https:\/\/doi.org\/10.1007\/s40262-018-0682-1.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"664_CR16","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/inf.0b013e3182a743c7","volume":"33","author":"JJ Cies","year":"2014","unstructured":"Cies JJ, Shankar V, Schlichting C, Kuti JL. Population pharmacokinetics of piperacillin\/tazobactam in critically ill young children. Pediatr Infect Dis J. 2014;33(2):168\u201373. https:\/\/doi.org\/10.1097\/inf.0b013e3182a743c7.","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"664_CR17","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/ftd.0b013e3182587665","volume":"34","author":"M Cohen-Wolkowiez","year":"2012","unstructured":"Cohen-Wolkowiez M, Benjamin DK Jr, Ross A, James LP, Sullivan JE, Walsh MC, et al. Population pharmacokinetics of piperacillin using scavenged samples from preterm infants. Ther Drug Monit. 2012;34(3):312\u20139. https:\/\/doi.org\/10.1097\/ftd.0b013e3182587665.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"664_CR18","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1128\/aac.02139-13","volume":"58","author":"M Cohen-Wolkowiez","year":"2014","unstructured":"Cohen-Wolkowiez M, Watt KM, Zhou C, Bloom BT, Poindexter B, Castro L, et al. Developmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants. Antimicrob Agents Chemother. 2014;58(5):2856\u201365. https:\/\/doi.org\/10.1128\/aac.02139-13.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"664_CR19","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1093\/jac\/dkx093","volume":"72","author":"PAJG De Cock","year":"2017","unstructured":"De Cock PAJG, van Dijkman SC, de Jaeger A, Willems J, Carlier M, Verstraete AG, et al. Dose optimization of piperacillin\/ tazobactam in critically ill children. J Antimicrob Chemother. 2017;72(7):2002\u201311. https:\/\/doi.org\/10.1093\/jac\/dkx093.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"664_CR20","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s00228-012-1413-4","volume":"69","author":"Z Li","year":"2013","unstructured":"Li Z, Chen Y, Li Q, Cao D, Shi W, Cao Y, et al. Population pharmacokinetics of piperacillin\/tazobactam in neonates and young infants. Eur J Clin Pharmacol. 2013;69(6):1223\u201333. https:\/\/doi.org\/10.1007\/s00228-012-1413-4.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"664_CR21","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1128\/aac.02089-15","volume":"60","author":"K Nichols","year":"2015","unstructured":"Nichols K, Chung EK, Knoderer CA, Buenger LE, Healy DP, Dees J, et al. Population pharmacokinetics and pharmacodynamics of extended-infusion piperacillin and tazobactam in critically ill children. Antimicrob Agents Chemother. 2015;60(1):522\u201331. https:\/\/doi.org\/10.1128\/aac.02089-15.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"664_CR22","doi-asserted-by":"publisher","first-page":"e01260","DOI":"10.1128\/aac.01260-19","volume":"63","author":"C Thibault","year":"2019","unstructured":"Thibault C, Lavigne J, Litalien C, Kassir N, Theoret Y, Autmizguine J. Population pharmacokinetics and safety of piperacillin-tazobactam extended infusions in infants and children. Antimicrob Agents Chemother. 2019;63(11):e01260-e1319. https:\/\/doi.org\/10.1128\/aac.01260-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"664_CR23","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/pbc.25287","volume":"62","author":"JJ Cies","year":"2015","unstructured":"Cies JJ, Jain J, Kuti JL. Population pharmacokinetics of the piperacillin component of piperacillin\/tazobactam in pediatric oncology patients with fever and neutropenia. Pediatr Blood Cancer. 2015;62(3):477\u201382. https:\/\/doi.org\/10.1002\/pbc.25287.","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"664_CR24","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s40262-015-0291-1","volume":"54","author":"S Leroux","year":"2015","unstructured":"Leroux S, Turner MA, Guellec CB, et al. Pharmacokinetic studies in neonates: the utility of an opportunistic sampling design. Clin Pharmacokinet. 2015;54(12):1273\u201385. https:\/\/doi.org\/10.1007\/s40262-015-0291-1.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"664_CR25","doi-asserted-by":"publisher","first-page":"E475","DOI":"10.1208\/aapsj070248","volume":"7","author":"B Meibohm","year":"2005","unstructured":"Meibohm B, Laer S, Panetta JC, Barrett JS. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J. 2005;7(2):E475\u201387. https:\/\/doi.org\/10.1208\/aapsj070248.","journal-title":"AAPS J"},{"issue":"9","key":"664_CR26","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1002\/jps.23574","volume":"102","author":"N Holford","year":"2013","unstructured":"Holford N, Heo YA, Anderson B. A pharmacokinetic standard for babies and aduts. J Pharm Sci. 2013;102(9):2941\u201352. https:\/\/doi.org\/10.1002\/jps.23574.","journal-title":"J Pharm Sci"},{"issue":"2","key":"664_CR27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, et al. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351. https:\/\/doi.org\/10.1208\/s12248-011-9255-z.","journal-title":"AAPS J"},{"key":"664_CR28","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 33rd ed. CLSI supplement M100. 2023."},{"key":"664_CR29","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 13.0, 2023. Available from: http:\/\/www.eucast.org. Accessed 26 Oct 2024."},{"issue":"Suppl. 1","key":"664_CR30","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1086\/344653","volume":"36","author":"GL Drusano","year":"2003","unstructured":"Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis. 2003;36(Suppl. 1):S42-50. https:\/\/doi.org\/10.1086\/344653.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"664_CR31","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/cid\/cis857","volume":"56","author":"ME Falagas","year":"2013","unstructured":"Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin\/tazobactam: a systematic review and meta-analysis. Clin Infect Dis. 2013;56(2):272\u201382. https:\/\/doi.org\/10.1093\/cid\/cis857.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"664_CR32","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1164\/rccm.201601-0024oc","volume":"194","author":"JA Roberts","year":"2016","unstructured":"Roberts JA, Abdul-Aziz MH, Davis JS, Dulhunty JM, Cotta MO, Myburgh J, et al. Continuous versus intermittent beta-lactam infusion in severe sepsis: a meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med. 2016;194(6):681\u201391. https:\/\/doi.org\/10.1164\/rccm.201601-0024oc.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"664_CR33","doi-asserted-by":"publisher","first-page":"e02486","DOI":"10.1128\/AAC.02486-17","volume":"62","author":"ZR Shi","year":"2018","unstructured":"Shi ZR, Chen XK, Tian LY, Wang YK, Zhang GY, Dong L, et al. Population pharmacokinetics and dosing optimization of ceftazidime in infants. Antimicrob Agents Chemother. 2018;62(4):e02486-e2517. https:\/\/doi.org\/10.1128\/AAC.02486-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"664_CR34","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/jcph.1865","volume":"61","author":"ED Por","year":"2021","unstructured":"Por ED, Akers KS, Chung KK, Livezey JR, Selig DJ. Population pharmacokinetic modeling and simulations of imipenem in burn patients with and without continuous venovenous hemofiltration in the military health system. J Clin Pharmacol. 2021;61(9):1182\u201394. https:\/\/doi.org\/10.1002\/jcph.1865.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"664_CR35","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/a:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28(5):481\u2013504. https:\/\/doi.org\/10.1023\/a:1012299115260.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"664_CR36","doi-asserted-by":"publisher","DOI":"10.4172\/jbb.10000e12","author":"M Dorababu","year":"2012","unstructured":"Dorababu M. Pharmacokinetic modeling of data with below quantification limit. J Bioequiv. 2012. https:\/\/doi.org\/10.4172\/jbb.10000e12.","journal-title":"J Bioequiv."},{"issue":"11","key":"664_CR37","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1128\/aac.40.11.2658","volume":"40","author":"SJ van den Hazel","year":"1996","unstructured":"van den Hazel SJ, de Vries XH, Speelman P, Dankert J, Tytgat GN, Huibregtse K, et al. Biliary excretion of ciprofloxacin and piperacillin in the obstructed biliary tract. Antimicrob Agents Chemother. 1996;40(11):2658\u201360. https:\/\/doi.org\/10.1128\/aac.40.11.2658.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"664_CR38","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1093\/jac\/dkx541","volume":"73","author":"TW Felton","year":"2018","unstructured":"Felton TW, Ogungbenro K, Boselli E, Hope WW, Rodvold KA. Comparison of piperacillin exposure in the lungs of critically ill patients and healthy volunteers. J Antimicrob Chemother. 2018;73(5):1340\u20137. https:\/\/doi.org\/10.1093\/jac\/dkx541.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"664_CR39","doi-asserted-by":"publisher","first-page":"552","DOI":"10.2215\/cjn.04180510","volume":"6","author":"J Bacchetta","year":"2011","unstructured":"Bacchetta J, Cochat P, Rognant N, Ranchin B, Hadj-Aissa A, et al. Which creatinine and cystatin C equations can be reliably used in children? Clin J Am Soc Nephrol. 2011;6(3):552\u201360. https:\/\/doi.org\/10.2215\/cjn.04180510.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"664_CR40","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1542\/peds.58.2.259","volume":"58","author":"GJ Schwartz","year":"1976","unstructured":"Schwartz GJ, Haycock GB, Edelmann CM Jr, et al. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics. 1976;58(2):259\u201363.","journal-title":"Pediatrics"},{"issue":"4","key":"664_CR41","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/ajh.25390","volume":"94","author":"JD Lebensburger","year":"2019","unstructured":"Lebensburger JD, Aban I, Pernell B, Kasztan M, Feig DI, Hilliard LM, et al. Hyperfiltration during early childhood precedes albuminuria in pediatric sickle cell nephropathy. Am J Hematol. 2019;94(4):417\u201323. https:\/\/doi.org\/10.1002\/ajh.25390.","journal-title":"Am J Hematol"},{"issue":"3","key":"664_CR42","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.22374\/1710-6222.24.1.3.3","volume":"24","author":"C Thibault","year":"2017","unstructured":"Thibault C, Kassir N, Theoret Y, Varin F, Litalien C, Autmizguine J. Dose-exposure simulation for piperacillin-tazobactam dosing strategies in infants and young children. J Popul Ther Clin Pharmacol. 2017;24(3):e33-344. https:\/\/doi.org\/10.22374\/1710-6222.24.1.3.3.","journal-title":"J Popul Ther Clin Pharmacol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-024-00664-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-024-00664-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-024-00664-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T05:40:46Z","timestamp":1738042846000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-024-00664-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["664"],"URL":"https:\/\/doi.org\/10.1007\/s40272-024-00664-4","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"assertion":[{"value":"20 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the National Key Research and Development Program of China (2023YFC2706100), the National Natural Science Foundation of China (82173897), the\u00a0Distinguished Young and Middle-aged Scholar of Shandong University,\u00a0and the Taishan Scholar Program of Shandong Province (tstp20230660).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Totsapol Jirasomprasert, Li-Yuan Tian, Dian-Ping You, Ya-Kun Wang, Lei Dong, Ya-Hui Zhang, Guo-Xiang Hao, John van den Anker, Yue-E Wu, Bo-Hao Tang, Wei Zhao, and Yi Zheng have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Approval was obtained from the institutional ethics committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was obtained from all parents of the children included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The research code is available from the corresponding author upon reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"TJ analyzed and interpreted the data for the work, drafted the initial manuscript, and revised the manuscript. L-YT, D-PY, Y-KW, and LD collected the clinical data. G-XH and Y-HZ determined the samples. JvdA and Y-EW provided advice and critically reviewed and revised the manuscript. B-HT, WZ, and YZ contributed equally to the design of the work, supervised the data collection, and critically reviewed and revised the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}